Last Updated:
10 Mar 2026, 03:30:01 PM (IST)
Gufic Biosciences Limited
NSE: GUFICBIO BSE: GUFICBIO
NSE
289.65
12.05 (4.34%)
Prev Close
277.6
Open Price
278.05
Volume
71,884
Today Low / High
277.55 / 293.9
52 WK Low / High
268 / 407.85
Range
275 - 304
BSE
290.40
13.55 (4.89%)
Prev Close
276.85
Open Price
276.9
Volume
2,073
Today Low / High
276.9 / 293.6
52 WK Low / High
268.65 / 409
Range
276 - 305
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 289.65 (target range: 275 - 304), reflecting a change of 12.05 (4.34078%). On the BSE, it is listed at 290.4 (target range: 276 - 305), showing a change of 13.55 (4.89435%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
275.00
1.29%
27 Feb
281.05
0.71%
26 Feb
278.75
1.17%
25 Feb
281.15
-0.66%
24 Feb
283.55
-0.86%
23 Feb
288.45
-1.72%
20 Feb
287.40
0.40%
19 Feb
294.90
-2.76%
18 Feb
292.95
0.92%
Gufic Biosciences Limited Graph
Gufic Biosciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Gufic Biosciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 289.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 290.40 | 293.30 | 263.97 - 322.63 |
| 296.21 | 236.97 - 355.45 | ||
| 299.11 | 209.38 - 388.85 | ||
| Bearish Scenario | 290.40 | 287.50 | 258.75 - 316.25 |
| 284.59 | 227.67 - 341.51 | ||
| 281.69 | 197.18 - 366.19 |
Overview of Gufic Biosciences Limited
ISIN
INE742B01025
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
35,954
Market Cap
27,933,692,046
Last Dividend
0.1
Official Website
IPO Date
2004-10-19
DCF Diff
561.59
DCF
-275
Financial Ratios Every Investor Needs
Stock Dividend of GUFICBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-22 | September 22, 25 | 0.1 | 0.1 | 2025-09-22 | 2025-10-29 | |
| 2024-09-17 | September 17, 24 | 0.1 | 0.1 | 2024-09-18 | 2024-10-25 | |
| 2023-09-21 | September 21, 23 | 0.1 | 0.1 | 2023-09-21 | 2023-10-29 | |
| 2022-08-24 | August 24, 22 | 0.1 | 0.1 | 2022-08-25 | 2022-09-29 | |
| 2021-09-09 | September 09, 21 | 0.1 | 0.1 | 2021-09-13 | 2021-10-18 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 819.81 Cr | 522.82 Cr | 296.99 Cr | 0.3623 | 5.64 Cr | 128.80 Cr | 113.63 Cr | 69.65 Cr | 6.96 | 138.32 Cr | 0.0850 |
| 2024-03-31 | 806.67 Cr | 399.29 Cr | 407.37 Cr | 0.5050 | 5.44 Cr | 111.10 Cr | 289.38 Cr | 86.14 Cr | 8.74 | 148.05 Cr | 0.1068 |
| 2023-03-31 | 690.62 Cr | 340.90 Cr | 351.34 Cr | 0.5087 | 5.16 Cr | 14.90 Cr | 252.12 Cr | 79.70 Cr | 8.22 | 137.23 Cr | 0.1154 |
| 2022-03-31 | 779.16 Cr | 422.82 Cr | 356.34 Cr | 0.4573 | 4.43 Cr | 16.43 Cr | 129.10 Cr | 95.84 Cr | 9.89 | 148.49 Cr | 0.1230 |
| 2021-03-31 | 487.70 Cr | 256.51 Cr | 231.19 Cr | 0.4740 | 2.10 Cr | 9.20 Cr | 68.15 Cr | 44.23 Cr | 4.56 | 85.78 Cr | 0.0907 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 29.02 Cr | 1,169.36 Cr | 568.29 Cr | 601.0768 Cr | 336.19 Cr | 307.17 Cr | 216.87 Cr | 521.46 Cr | 0.00 Cr | 0.00 Cr | 11.74 Cr | 387.5572 Cr |
| 2024-03-31 | 1.14 Cr | 1,092.54 Cr | 559.98 Cr | 532.5605 Cr | 332.92 Cr | 331.78 Cr | 200.48 Cr | 474.17 Cr | 3.85 Cr | 4.97 Cr | 1.78 Cr | 372.0489 Cr |
| 2023-03-31 | 28.60 Cr | 861.16 Cr | 513.35 Cr | 347.8082 Cr | 334.19 Cr | 305.59 Cr | 183.46 Cr | 328.48 Cr | 5.36 Cr | 4.96 Cr | -0.18 Cr | 288.2075 Cr |
| 2022-03-31 | 11.61 Cr | 521.40 Cr | 252.28 Cr | 269.1180 Cr | 64.39 Cr | 52.78 Cr | 115.57 Cr | 155.43 Cr | -0.58 Cr | 5.00 Cr | 0.01 Cr | 186.4016 Cr |
| 2021-03-31 | 6.20 Cr | 392.06 Cr | 218.62 Cr | 173.4366 Cr | 61.54 Cr | 55.34 Cr | 94.40 Cr | 118.46 Cr | 2.83 Cr | 5.00 Cr | 0.01 Cr | 163.6624 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 102.6217 Cr | -71.7091 Cr | -16.3260 Cr | 27.0962 Cr | 27.8655 Cr | 29.0222 Cr | -75.5255 Cr | 69.6495 Cr | -6.7432 Cr | -1.0028 Cr | -16.3869 Cr |
| 2024-03-31 | -7.4571 Cr | -102.3889 Cr | 82.3810 Cr | -120.1516 Cr | -27.4651 Cr | 1.1368 Cr | -112.6945 Cr | 86.1356 Cr | 5.5070 Cr | -0.9720 Cr | -17.0246 Cr |
| 2023-03-31 | -26.5872 Cr | -190.7265 Cr | 234.3076 Cr | -214.1879 Cr | 16.9939 Cr | 28.6019 Cr | -187.6007 Cr | 79.7048 Cr | 250.0924 Cr | -1.0437 Cr | -67.8907 Cr |
| 2022-03-31 | 106.2395 Cr | -94.5891 Cr | -6.2437 Cr | 18.7864 Cr | 5.4067 Cr | 11.6081 Cr | -87.4531 Cr | 95.8401 Cr | 5.8934 Cr | -0.9211 Cr | -21.1623 Cr |
| 2021-03-31 | 87.2509 Cr | -6.6929 Cr | -78.6180 Cr | 74.8515 Cr | 1.9400 Cr | 6.2014 Cr | -12.3994 Cr | 44.2316 Cr | -61.3922 Cr | -0.3629 Cr | 28.0568 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 231.41 Cr | 148.80 Cr | 82.61 Cr | 0.3570 | 25.29 Cr | 12.42 Cr | 1.24 | 32.98 Cr | 0.0537 |
| 2025-09-30 | 237.05 Cr | 104.44 Cr | 132.62 Cr | 0.5594 | 30.07 Cr | 16.82 Cr | 1.68 | 39.96 Cr | 0.0710 |
| 2025-06-30 | 223.72 Cr | 100.77 Cr | 122.95 Cr | 0.5496 | 25.58 Cr | 13.07 Cr | 1.30 | 34.23 Cr | 0.0584 |
| 2025-03-31 | 205.02 Cr | 133.09 Cr | 71.93 Cr | 0.3509 | 18.53 Cr | 7.72 Cr | 0.77 | 26.77 Cr | 0.0377 |
| 2024-12-31 | 207.79 Cr | 94.17 Cr | 113.63 Cr | 0.5468 | 29.31 Cr | 19.31 Cr | 1.93 | 35.79 Cr | 0.0929 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 74.60 Cr | 13.48 Cr | 88.08 Cr | 324.70 Cr | 229.66 Cr | 727.21 Cr | 512.74 Cr | 1,271.11 Cr | 639.94 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 29.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -601.08 Cr |
| 2025-03-31 | 29.02 Cr | 0.00 Cr | 29.02 Cr | 314.93 Cr | 216.87 Cr | 624.52 Cr | 521.46 Cr | 1,169.36 Cr | 568.29 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 19.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -574.18 Cr |
| 2024-09-30 | 5.74 Cr | 13.66 Cr | 19.40 Cr | 0.35 Cr | 186.84 Cr | 578.39 Cr | 506.12 Cr | 1,104.67 Cr | 530.49 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 13.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 7.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 19.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 21.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 20.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
President of Operation
Ashok Dev
Gender: male
Year Born:
Investor Relations Officer
Avik Das
Gender: male
Year Born:
Chief Financial Officer
Devkinandan Roonghta
Gender: male
Year Born: 1965
Chairman & MD
Jayesh Pannalal Choksi
Gender: male
Year Born: 1954
Chief Operating Officer
Nagesh Yarrabathina
Gender: male
Year Born:
Whole-Time Director
Pankaj Jayakumar Gandhi
Gender: male
Year Born: 1959
Senior Manager of Legal, Company Secretary & Compliance Officer
Ami Naresh Shah
Gender: female
Year Born:
Associate Vice President - Sales & Marketing
Pinak Padhya
Gender: male
Year Born:
Chief Executive Officer & Whole Time Director
Pranav Jayesh Choksi
Gender: male
Year Born: 1983
Head Human Resource Department
Sunil Desai
Gender: male
Year Born:
FAQs about Gufic Biosciences Limited
Who is the CEO of the company?
The CEO is Pranav Jayesh Choksi.
What is the current market price of the stock?
The current price is ₹278.55.
What is the 52-week price range?
The range is ₹271.9-407.85.
What is the market capitalization of the company?
The market capitalization is ₹2,793.37 crores.
What is the dividend yield?
The dividend yield is 0.04%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 55.83.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Gufic Biosciences Limited (ISIN: INE742B01025) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,793.37 crores and an average daily volume of 35,954 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.1.